JP2020514290A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514290A5 JP2020514290A5 JP2019536228A JP2019536228A JP2020514290A5 JP 2020514290 A5 JP2020514290 A5 JP 2020514290A5 JP 2019536228 A JP2019536228 A JP 2019536228A JP 2019536228 A JP2019536228 A JP 2019536228A JP 2020514290 A5 JP2020514290 A5 JP 2020514290A5
- Authority
- JP
- Japan
- Prior art keywords
- drug delivery
- polypeptide
- preparation
- cancer
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012377 drug delivery Methods 0.000 claims 33
- 229920001184 polypeptide Polymers 0.000 claims 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims 30
- 238000009472 formulation Methods 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 13
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 12
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 238000001990 intravenous administration Methods 0.000 claims 8
- 238000010253 intravenous injection Methods 0.000 claims 8
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 101000712669 Homo sapiens TGF-beta receptor type-2 Proteins 0.000 claims 3
- 108090000144 Human Proteins Proteins 0.000 claims 3
- 102000003839 Human Proteins Human genes 0.000 claims 3
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 210000004085 squamous epithelial cell Anatomy 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000037844 advanced solid tumor Diseases 0.000 claims 1
- 210000000270 basal cell Anatomy 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 239000012931 lyophilized formulation Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 210000000713 mesentery Anatomy 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000001989 nasopharynx Anatomy 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 230000000955 neuroendocrine Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443698P | 2017-01-07 | 2017-01-07 | |
| US62/443,698 | 2017-01-07 | ||
| US201762581978P | 2017-11-06 | 2017-11-06 | |
| US62/581,978 | 2017-11-06 | ||
| PCT/US2018/012604 WO2018129331A1 (en) | 2017-01-07 | 2018-01-05 | Dosing regimens and dosage forms for targeted tgf-b inhibition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020514290A JP2020514290A (ja) | 2020-05-21 |
| JP2020514290A5 true JP2020514290A5 (enExample) | 2021-02-18 |
Family
ID=62791283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536228A Pending JP2020514290A (ja) | 2017-01-07 | 2018-01-05 | 標的ｔｇｆ−β阻害のための投薬計画及び投薬形態 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20190330375A1 (enExample) |
| EP (1) | EP3565599A4 (enExample) |
| JP (1) | JP2020514290A (enExample) |
| KR (1) | KR20190102059A (enExample) |
| CN (1) | CN110198738A (enExample) |
| AU (1) | AU2018205233A1 (enExample) |
| BR (1) | BR112019013924A2 (enExample) |
| CA (1) | CA3048646A1 (enExample) |
| CL (1) | CL2019001871A1 (enExample) |
| IL (1) | IL267856A (enExample) |
| MX (1) | MX2019008001A (enExample) |
| PH (1) | PH12019501574A1 (enExample) |
| RU (1) | RU2019124875A (enExample) |
| SG (1) | SG11201906157YA (enExample) |
| WO (1) | WO2018129331A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1225740A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma Inc. | TGF-β受体II型变体及其用途 |
| EP3331550B1 (en) | 2015-08-04 | 2022-11-02 | Acceleron Pharma Inc. | Composition for treating myeloproliferative disorders |
| EP4241848A3 (en) | 2017-05-04 | 2023-11-01 | Acceleron Pharma Inc. | Tgf-beta receptor type ii fusion proteins and uses thereof |
| MX2020014166A (es) * | 2018-06-22 | 2021-03-09 | Merck Patent Gmbh | Regímenes de dosis para la inhibición dirigida del factor de crecimiento transformante beta (tgf-b) para usarse en el tratamiento de cáncer del tracto biliar. |
| AU2019299318A1 (en) * | 2018-07-02 | 2021-01-21 | Merck Patent Gmbh | Combination therapy with targeted TGF-B inhibition for treatment of advanced non-small cell lung cancer |
| KR20210042909A (ko) | 2018-07-09 | 2021-04-20 | 프레시전 인코포레이티드 | 융합 구조물 및 그의 이용 방법 |
| KR102881644B1 (ko) * | 2018-11-09 | 2025-11-06 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | TGF-β 수용체 융합 단백질 약학적 조성물 및 이의 용도 |
| TW202043267A (zh) | 2019-01-30 | 2020-12-01 | 美商供石公司 | TGFβ之LTBP複合物專一性抑制劑及其用途 |
| EP3929215A4 (en) * | 2019-06-10 | 2022-06-22 | Shandong Boan Biotechnology Co., Ltd. | BIFUNCTIONAL FUSION PROTEIN AGAINST PDL1 AND TGF? AND ITS USE |
| CN112574314A (zh) * | 2019-09-30 | 2021-03-30 | 和铂医药(苏州)有限公司 | 一种融合蛋白及其应用 |
| WO2021081321A1 (en) * | 2019-10-24 | 2021-04-29 | Amgen Inc. | Systems and approaches for drug delivery |
| AU2020375161A1 (en) * | 2019-11-01 | 2022-05-19 | Ares Trading S.A. | Combined inhibition of PD-1, TGFβ and ATM together with radiotherapy for the treatment of cancer |
| EP4054617A4 (en) * | 2019-11-05 | 2023-12-27 | Acceleron Pharma Inc. | Treatments for systemic sclerosis |
| CA3158047A1 (en) * | 2019-12-11 | 2021-06-17 | Yunying CHEN | Bi-functional antibody against pd-l1 and tgf? |
| CA3161504A1 (en) * | 2019-12-20 | 2021-06-24 | Chiara IORIO | Igg:tgf.beta.rii fusion protein composition |
| CN111118064B (zh) * | 2019-12-24 | 2022-10-25 | 华南理工大学 | 一种精子生成障碍动物模型及其制备方法与应用 |
| JP2023511255A (ja) | 2020-01-11 | 2023-03-17 | スカラー ロック インコーポレイテッド | ＴＧＦ－β阻害剤及びその使用 |
| WO2021142427A1 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock, Inc. | TGFβ INHIBITORS AND USE THEREOF |
| US20230093512A1 (en) * | 2020-02-18 | 2023-03-23 | Nanjing GenScript Biotech Co., Ltd. | Fusion proteins and uses thereof |
| TWI813951B (zh) * | 2020-02-25 | 2023-09-01 | 大陸商上海藥明生物技術有限公司 | 一種雙功能融合蛋白及其用途 |
| AU2021305234A1 (en) | 2020-07-10 | 2023-02-09 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| WO2022063193A1 (zh) * | 2020-09-24 | 2022-03-31 | 上海齐鲁制药研究中心有限公司 | 同时靶向PD-L1和TGFβ的双功能分子及其医药用途 |
| EP4306131A4 (en) | 2021-03-08 | 2025-06-18 | Nanjing GenScript Biotech Co., Ltd. | ANTIBODY DELIVERY USING A DUAL VIRAL VECTOR SYSTEM |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| JP2024542879A (ja) * | 2021-11-19 | 2024-11-18 | メルス ナムローゼ フェンノートシャップ | Ｐｄ－１およびｔｇｆ－ｂｒｉｉ結合ドメインを含む多重特異性結合部位 |
| WO2024187051A1 (en) | 2023-03-07 | 2024-09-12 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
| WO2025240343A1 (en) | 2024-05-13 | 2025-11-20 | Scholar Rock, Inc. | Tgf-beta inhibitors for treating cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5785682A (en) * | 1995-03-22 | 1998-07-28 | Abbott Laboratories | Pre-filled syringe drug delivery system |
| PL2542590T5 (pl) * | 2010-03-05 | 2020-08-10 | The Johns Hopkins University | Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych |
| US20130110045A1 (en) * | 2011-10-31 | 2013-05-02 | Ming-Yuan Wu | Single use intravenous therapy administering device with needle safety covers |
| NZ701821A (en) * | 2012-04-30 | 2016-06-24 | Biocon Ltd | Targeted/immunomodulatory fusion proteins and methods for making same |
| JP6720075B2 (ja) * | 2013-05-31 | 2020-07-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 癌のための併用療法 |
| SG10202108879SA (en) * | 2014-02-10 | 2021-09-29 | Merck Patent Gmbh | TARGETED TGFβ INHIBITION |
| CA2964367C (en) * | 2014-10-14 | 2024-01-30 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| CA2975147C (en) * | 2015-01-31 | 2025-06-10 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS OF ADMINISTRATION OF THERAPEUTIC MOLECULES TO T CELLS |
| CN108136001B (zh) * | 2015-04-03 | 2022-07-29 | 佐马技术有限公司 | 使用TGF-β抑制剂和PD-1抑制剂治疗癌症 |
| RS61152B2 (sr) * | 2015-05-12 | 2024-06-28 | Hoffmann La Roche | Terapeutski i dijagnostički postupci za lečenje raka |
-
2018
- 2018-01-05 AU AU2018205233A patent/AU2018205233A1/en not_active Abandoned
- 2018-01-05 BR BR112019013924-9A patent/BR112019013924A2/pt not_active Application Discontinuation
- 2018-01-05 CA CA3048646A patent/CA3048646A1/en active Pending
- 2018-01-05 EP EP18736497.1A patent/EP3565599A4/en active Pending
- 2018-01-05 SG SG11201906157YA patent/SG11201906157YA/en unknown
- 2018-01-05 RU RU2019124875A patent/RU2019124875A/ru unknown
- 2018-01-05 CN CN201880006085.0A patent/CN110198738A/zh active Pending
- 2018-01-05 KR KR1020197022795A patent/KR20190102059A/ko not_active Ceased
- 2018-01-05 WO PCT/US2018/012604 patent/WO2018129331A1/en not_active Ceased
- 2018-01-05 JP JP2019536228A patent/JP2020514290A/ja active Pending
- 2018-01-05 MX MX2019008001A patent/MX2019008001A/es unknown
-
2019
- 2019-07-02 US US16/460,792 patent/US20190330375A1/en not_active Abandoned
- 2019-07-03 PH PH12019501574A patent/PH12019501574A1/en unknown
- 2019-07-04 IL IL267856A patent/IL267856A/en unknown
- 2019-07-05 CL CL2019001871A patent/CL2019001871A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514290A5 (enExample) | ||
| Zhang et al. | Toripalimab: the first domestic anti-tumor PD-1 antibody in China | |
| Bianco et al. | Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide | |
| Singh et al. | Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer | |
| JP2019527706A5 (enExample) | ||
| FI3833386T3 (fi) | Monispesifisiä sitoutuvia proteiineja, jotka sitovat her2:ta, nkg2d:tä ja cd16:ta, ja käyttömenetelmiä | |
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| RU2019106663A (ru) | Комбинированная терапия рака | |
| JP2017506217A5 (enExample) | ||
| JP2016528195A5 (enExample) | ||
| JP2020508317A5 (enExample) | ||
| RU2018135317A (ru) | Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии | |
| JP2016520082A5 (enExample) | ||
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| RU2014138474A (ru) | Новые модуляторы и способы применения | |
| JP2019503349A5 (enExample) | ||
| TW202019487A (zh) | 抗體-藥物結合物及微管蛋白抑制劑之組合 | |
| Becker et al. | Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy | |
| RU2016147206A (ru) | Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака | |
| JP2015514113A (ja) | 単一特異性および二重特異性抗ｉｇｆ−１ｒおよび抗ｅｒｂｂ３抗体の用法および用量 | |
| JP2018516966A5 (enExample) | ||
| Kanat et al. | Metastatic gastric cancer treatment: a little slow but worthy progress | |
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| FI3355919T3 (fi) | Yhdistelmähoito ihmisen kasvu- ja erilaistumistekijä 15:n (GDF-15) inhibiittoreita ja immuunitarkistuspiste-estäjiä käyttämällä | |
| JP2020517658A5 (enExample) |